[1] Blobner M, Frick CG, Stauble RB, et al. Neuromuscular blockade improves surgical conditions (NISCO). Surg Endosc 2015; 29: 627–36.
[2] Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ 2012; 345: e6329.
[3] Kheterpal S, Vaughn MT, Dubovoy TZ, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): A multi-center matched cohort analysis. Anesthesiology 2020; 132:1371–81
[4] Kim NY, Koh JC, Lee KY, et al. Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded, controlled study. J Clin Anesth 2019; 57:97-102
[5] Togioka BM, Yanez D, Aziz MF, Higgins JR, Tekkali P, Treggiari MM. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. Br J Anaesth 2020; 124:553-561.
[6] Bulka CM, Terekhov MA, Martin BJ, Dmochowski RR, Hayes RM, Ehrenfeld JM. Nondepolarizing neuromuscular blocking agents, reversal, and risk of postoperative pneumonia. Anesthesiology 2016; 125: 647–55.
[7] Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex. Minerva Anestesiol 2016; 82: 735-42.
[8] Naguib M, Brull SJ, Kopman AF, et al. Consensus statement on perioperative use of neuromuscular monitoring. Anesth Analg 2018; 127: 71e80.
[9] Plaud B, Baillard C, Bourgain JL, et al. Guidelines on muscle relaxants and reversal in anaesthesia. Anaesth Crit Care Pain Med 2020;39(1):125-142.
[10] Checketts MR, Alladi R, Ferguson K, et al (2016), Recommendations for standards of monitoring during anaesthesia and recovery 2015 : Association of Anaesthetists of Great Britain and Ireland. Anaesthesia].
[11] Stoelting RK. Monitoring of neuromuscular blockade: what would you expect if you were the patient? APSF Newsletter. 2016;30:45,47. https://www.apsf.org/article/monitoring-of-neuromuscular-blockade-what-would-you-expect-if-you-were-the-patient/ [Accessed 27 April 2020]
[12] Hyman EC, Brull SJ. Clarification: Current Status of Neuromuscular Reversal and Monitoring, Challenges and Opportunities. Anesthesiology 2017; 127: 730.
[13] Todd MM, Hindman BJ, King BJ. The implementation of quantitative electromyographic neuromuscular monitoring in an academic anesthesia department. Anesth Analg 2014; 119:323–331.
[14] Kirmeier E, Eriksson LI, Lewald H, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med 2019; 7: 129-140.
[15] Mazo V, Sabaté S, Canet J, et al. Prospective external validation of a predictive score for postoperative pulmonary complications. Anesthesiology 2014; 121: 219-31.
[16] Canet J, Hardman J, Sabaté S, et al. PERISCOPE study: predicting post-operative pulmonary complications in Europe: European Journal of Anaesthesiology. 2011;28(6):459-461.
[17] Kotake Y, Ochiai R, Suzuki T, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block: Anesthesia & Analgesia. 2013;117(2):345-351.
[18] Cammu G. Residual Neuromuscular Blockade and Postoperative Pulmonary Complications: What Does the Recent Evidence Demonstrate? Curr Anesthesiol Rep 2020; 27:1-6.
[19] Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2018; 73:631-641
[20] Errando CL, Garutti I, Mazzinari G, Díaz-Cambronero Ó, Bebawy JF. Residual neuromuscular blockade in the postanesthesia care unit: observational cross-sectional study of a multicenter cohort. Minerva Anestesiol 2016; 82: 1267-1277.
[21] Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth 2015; 115: 743-51.
[22] Fuchs-Buder T, Nemes R, Schmartz D. Residual neuromuscular blockade: management and impact on postoperative pulmonary outcome. Curr Opin Anaesthesiol 2016; 29: 662-667
[23] Merck & Co. Bridion® (sugammadex) injection, for intravenous use: US prescribing information. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf [Accessed 27 April 2020]
[24] European Medicines Agency. Bridion® (sugammadex) 100 mg/ml solution for injection: EU summary of product characteristics. 2015. https://www.ema.europa.eu/en/medicines/human/EPAR/bridion [Accessed 27 April 2020]
[25] De Boer HD, Carlos RV, Brull SJ. Is lower-dose sugammadex a cost-saving strategy for reversal of deep neuromuscular block? Facts and fiction. BMC Anesthesiol 2018; 18: 159.
[26] Keating GM. Sugammadex: A Review of Neuromuscular Blockade Reversal. Drugs 2016; 76(10): 1041-52
[27] Alday E, Munoz M, Planas A, et al. Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial. Canad J Anesth 2019; 66:1328-37.
[28] Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia 2017; 72: 16-37.
[29] Ledowsky T, Hillyard S, O’Dea B, Archer R et al. Introduction of sugammadex as reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome. Indian J Anaesth 2013; 57: 46-51.
[30] Hunter JM. Reversal of residual neuromuscular block: complications associated with perioperative management of muscle relaxation. Br J Anaesth 2017; 119: i53-62.
[31] Unterbuchner C. Neuromuscular Block and Blocking Agents in 2018. Turk J Anaesthesiol Reanim 2018; 46: 75-80.
[32] Nemes R, Fülesdi B, Pongrácz A, et al. Impact of reversal strategies on the incidence of postoperative residual paralysis after rocuronium relaxation without neuromuscular monitoring: A partially randomised placebo controlled trial. Eur J Anaesthesiol 2017; 34: 609-616.
[33] Esteves S. Can residual paralysis be avoided? A critical appraisal of the use of sugammadex. Eur J Anaesthesiol 2015; 32: 663–665.
[34] McLean DJ, Diaz-Gil D, Farhan HN, Ladha KS, Kurth T, Eikermann M. Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Com- plications. Anesthesiology 2015; 122: 1201-13.
[35] Sasaki N, Meyer MJ, Malviya SA, Stanislaus AB, MacDonald T, Doran ME, et al. Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes: a prospective study. Anesthesiology 2014; 121: 959-68.
[36] Abad-Gurumeta A, Ripollés-Melchor J, Casans-Francés R, et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia 2015; 70: 1441-52.
[37] De la Quintana-Gordon FB, Nacarino-Alcorta B, Fajardo-Pérez M. [Basic lung ultrasound. Part 2. Parenchymal diseases]. Rev Esp Anestesiol Reanim 2015; 62: 337-49.
[38] Ferrando C, Soro M, Unzueta C, et al. Individualised perioperative open-lung approach versus standard protective ventilation in abdominal surgery (iPROVE): a randomised controlled trial. Lancet Respir Med 2018; 6: 193-203.
[39] Brown EN, Pavone KJ, Naranjo M. Multimodal General Anesthesia: Theory and Practice. Anesth Analg 2018; 127: 1246-1258.